Efficacy and Safety of Hypomethylating Agents in AML/MDS Patients Post Transplant
Author Information
Author(s): Wang Yaxin, Wang Qingyun, Ren Hanyun, Dong Yujun, Wang Qingya, Liang Zeyin, Yin Yue, Liu Wei, Xu Weilin, Han Na, Li Yuan
Primary Institution: Peking University First Hospital
Hypothesis
Can hypomethylating agents combined with Bcl-2 inhibitors improve outcomes for AML/MDS patients who relapse after allogeneic hematopoietic stem cell transplantation?
Conclusion
The study shows that combining hypomethylating agents with intensive chemotherapy improves survival rates for AML/MDS patients relapsing after transplantation, particularly for those at intermediate/high risk.
Supporting Evidence
- The median overall survival was 9 months, with a one-year survival rate of 41.5%.
- The overall response rate was 76.19% in the treatment group compared to 52.38% in the control group.
- Significant differences in overall survival were noted for patients with intermediate/high risk.
- No significant increase in adverse events was observed with the use of hypomethylating agents.
Takeaway
This study found that a special treatment helped some cancer patients live longer after their cancer came back, especially if they were at higher risk.
Methodology
The study was a retrospective cohort analysis of 42 patients treated at Peking University First Hospital from April 2012 to March 2022.
Potential Biases
Potential biases due to the retrospective nature of the study and single-center data collection.
Limitations
The study is limited by its small sample size and retrospective design.
Participant Demographics
The cohort included 26 males and 16 females with a median age of 41.5 years.
Statistical Information
P-Value
0.041
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website